These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30005420)

  • 21. Transmission of HIV and HCV within Former Soviet Union Countries.
    Aibekova L; Bexeitova A; Aldabergenova A; Hortelano G; Ge Z; Yi F; Shao Y; DeHovitz J; Vermund SH; Ali S
    Can J Gastroenterol Hepatol; 2020; 2020():9701920. PubMed ID: 32733822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012.
    Neaigus A; Reilly KH; Jenness SM; Hagan H; Wendel T; Gelpi-Acosta C; Marshall DM
    J Acquir Immune Defic Syndr; 2017 Jul; 75 Suppl 3(Suppl 3):S325-S332. PubMed ID: 28604434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan.
    Ruiseñor-Escudero H; Wirtz AL; Berry M; Mfochive-Njindan I; Paikan F; Yousufi HA; Yadav RS; Burnham G; Vu A
    Drug Alcohol Depend; 2014 Oct; 143():127-33. PubMed ID: 25131717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
    Enkelmann J; Gassowski M; Nielsen S; Wenz B; Roß S; Marcus U; Bremer V; Zimmermann R;
    Harm Reduct J; 2020 Jan; 17(1):7. PubMed ID: 31924208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.
    Des Jarlais DC; Cooper HLF; Arasteh K; Feelemyer J; McKnight C; Ross Z
    PLoS One; 2018; 13(3):e0194799. PubMed ID: 29596464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
    Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
    Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stomach cancer mortality in two large cohorts of migrants from the Former Soviet Union to Israel and Germany: are there implications for prevention?
    Ronellenfitsch U; Kyobutungi C; Ott JJ; Paltiel A; Razum O; Schwarzbach M; Winkler V; Becher H
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):409-16. PubMed ID: 19242359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey.
    Weill-Barillet L; Pillonel J; Semaille C; Léon L; Le Strat Y; Pascal X; Barin F; Jauffret-Roustide M
    Rev Epidemiol Sante Publique; 2016 Sep; 64(4):301-12. PubMed ID: 26904917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. History of detention and the risk of hepatitis C among people who inject drugs in Germany.
    Gassowski M; Nielsen S; Bannert N; Bock CT; Bremer V; Ross RS; Wenz B; Marcus U; Zimmermann R;
    Int J Infect Dis; 2019 Apr; 81():100-106. PubMed ID: 30658167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants.
    Folch C; Saludes V; Reyes-Ureña J; Antuori A; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2021 Apr; 90():103057. PubMed ID: 33310634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania.
    Kawambwa RH; Majigo MV; Mohamed AA; Matee MI
    BMC Public Health; 2020 Feb; 20(1):177. PubMed ID: 32019536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
    Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
    BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.
    Leprêtre A; Ba I; Lacombe K; Maynart M; Toufik A; Ndiaye O; Kane CT; Gozlan J; Tine J; Ndoye I; Raguin G; Girard PM
    J Int AIDS Soc; 2015; 18(1):19888. PubMed ID: 26004637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW).
    Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC
    Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of HIV and other infections and correlates of needle and syringe sharing among people who inject drugs in Podgorica, Montenegro: a respondent-driven sampling survey.
    Lausevic D; Begic S; Mugosa B; Terzic N; Vratnica Z; Labovic I; Bozicevic I
    Harm Reduct J; 2015 Feb; 12():2. PubMed ID: 25884194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
    van Beek I; Chronister KJ
    Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships.
    Morris MD; Neilands TB; Andrew E; Maher L; Page KA; Hahn JA
    Int J Drug Policy; 2017 Oct; 48():54-62. PubMed ID: 28804051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities.
    Heimer R; Eritsyan K; Barbour R; Levina OS
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S12. PubMed ID: 25253447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
    Corson S; Greenhalgh D; Taylor A; Palmateer N; Goldberg D; Hutchinson S
    Drug Alcohol Depend; 2013 Nov; 133(1):172-9. PubMed ID: 23791029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in risk behaviours and HIV status between primary amphetamines and opioid injectors in Estonia and Russia.
    Tavitian-Exley I; Maheu-Giroux M; Platt L; Heimer R; Uusküla A; Levina O; Vickerman P; Boily MC
    Int J Drug Policy; 2018 Mar; 53():96-105. PubMed ID: 29306786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.